Duck hepatitis A virus type 3 recombinant immunogen and application thereof
The invention discloses a duck hepatitis A virus type 3 (DHAV-3) recombinant immunogen and an application thereof. Prokaryotic expression is carried out after protective antigen dominant regions of DHAV-3 structural proteins VP1, VP3 and VP0 are connected in series through flexible Linker, a purified recombinant protein (rDHAV-3-VP) is used as an immunogen to immunize a 5-day-old SPF duckling, 1000 ELD50 DHAV-3 duck embryo homogenate virus is attacked in the 10th day after immunization, continuous observation is carried out for 21 days, an egg yolk antibody prevention group and a PBS control group are set at the same time, and the egg yolk antibody prevention group and the PBS control group are subjected to quantitative detection. Results show that an rDHAV-3-VP immune group and an egg yolk antibody prevention group provide the same protection rate, and the protection rates are both 82%; the titer of a serum neutralizing antibody of the survival ducklings after challenge of the immune group is 1: 48; the liver tissue lesion degree of the immune group is lower than that of the egg yolk antibody prevention group and that of the PBS control group, and the virus loads of the immune group and the egg yolk antibody prevention group have no difference and are remarkably lower than that of the PBS control group. The invention provides a new technical means for preventing DHAV-3 infection..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 17. Nov. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
MA BO [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-11-17, Last update posted on www.tib.eu: 2024-02-05, Last updated: 2024-02-09 |
|---|
| Patentnummer: |
CN117069866 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA019100566 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA019100566 | ||
| 003 | DE-627 | ||
| 005 | 20240209083536.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240202s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA019100566 | ||
| 035 | |a (EPA)CN117069866 | ||
| 035 | |a (EPA)88713793 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a MA BO |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Duck hepatitis A virus type 3 recombinant immunogen and application thereof |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-11-17, Last update posted on www.tib.eu: 2024-02-05, Last updated: 2024-02-09 | ||
| 520 | |a The invention discloses a duck hepatitis A virus type 3 (DHAV-3) recombinant immunogen and an application thereof. Prokaryotic expression is carried out after protective antigen dominant regions of DHAV-3 structural proteins VP1, VP3 and VP0 are connected in series through flexible Linker, a purified recombinant protein (rDHAV-3-VP) is used as an immunogen to immunize a 5-day-old SPF duckling, 1000 ELD50 DHAV-3 duck embryo homogenate virus is attacked in the 10th day after immunization, continuous observation is carried out for 21 days, an egg yolk antibody prevention group and a PBS control group are set at the same time, and the egg yolk antibody prevention group and the PBS control group are subjected to quantitative detection. Results show that an rDHAV-3-VP immune group and an egg yolk antibody prevention group provide the same protection rate, and the protection rates are both 82%; the titer of a serum neutralizing antibody of the survival ducklings after challenge of the immune group is 1: 48; the liver tissue lesion degree of the immune group is lower than that of the egg yolk antibody prevention group and that of the PBS control group, and the virus loads of the immune group and the egg yolk antibody prevention group have no difference and are remarkably lower than that of the PBS control group. The invention provides a new technical means for preventing DHAV-3 infection. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a LI HONGTAO |4 aut | |
| 700 | 0 | |a MEN JIAQI |4 aut | |
| 700 | 0 | |a YU LIDANYI |4 aut | |
| 700 | 0 | |a CHANG RUI |4 aut | |
| 700 | 0 | |a WANG WENYUE |4 aut | |
| 700 | 0 | |a CAO YONGSHENG |4 aut | |
| 700 | 0 | |a MIN YAHONG |4 aut | |
| 700 | 0 | |a ZHANG WENLONG |4 aut | |
| 700 | 0 | |a ZHANG GUIHONG |4 aut | |
| 700 | 0 | |a WANG JUNWEI |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 17. Nov. |
| 773 | 1 | 8 | |g year:2023 |g day:17 |g month:11 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/88713793/publication/CN117069866A1?q=CN117069866 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 17 |c 11 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 17 |c 11 | ||